You are herePharma News
(1st October, 2014); Think before prescribing broad spectrum antibiotics in children below 2 years of age. Researchers from Philadelphia published a report on last Monday states that the use of broad-spectrum antibiotics by children before the age of 24 months was associated with increased risk of obesity in early childhood.
Apollo Hospitals and Sanofi Announce Collaboration to Provide an Integrated Care Program in India for People with Diabetes
(30th September, 2014; Business Wire India); Apollo Hospitals and Sanofi today announced their decision to collaborate on the expansion of Apollo Sugar Clinics, which provide integrated diabetes care programs in India. Through this collaboration, Apollo and Sanofi plan to leverage their respective expertise in diabetes to provide patients with access to comprehensive educational resources, treatment and care programs that can help patients better manage their diabetes. The first wave of this collaboration will focus on the establishment of 50 Apollo Sugar Clinics.
(30th September, 2014; Business Wire India); For the Maharashtra government, addressing health issues ranks high on its list of priorities and the same is reflected through various policy interventions, innovative steps and strategies implemented to provide quality healthcare for all.
(30th September, 2014; Business Wire India); Fortis Healthcare announced on last friday (26th sept) that Fortis Mulund, one of its major hospitals in Mumbai has been conferred the prestigious British Medical Journal (BMJ) Award for ‘The Medical Team of the Year 2014.’ The honour was bestowed on the hospital for its outstanding “Antibiotic Review Program – and Antibiotic Restriction Policy.”
(30th September, 2014; Business Wire India); Fortis Healthcare has been awarded the prestigious 2014 ‘Porter Prize, for Value Based Healthcare’. The prize was given in recognition of the company’s outstanding performance in the industry and for redefining the idea of patient care and fundamentally challenging the economic models within the industry.
Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy
(20th September, 2014; Business Wire India); Boehringer Ingelheim obtains exclusive global rights for development and commercialisation of CureVac’s investigational therapeutic cancer vaccine CV9202CV9202 is based on CureVac’s mRNA technology (RNActive®) Clinical investigation of CV9202 will be initiated in at least two different lung cancer treatment settings, in combination with Boehringer Ingelheim’s afatinib* and in the chemo-radiation setting. The in-licensing of this investigational cancer compound adds a highly innovative new approach to Boehringer Ingelheim’s lung cancer development portfolio.
International SOS continues to provide expert advice to client organisations during the ongoing Ebola outbreak. This outbreak is unprecedented in its magnitude, multi-country spread, and impact on health services and economies.
(17th September, 2014); A 12 member Australian Life Sciences & Health Care delegation is visiting India from 15 to 19 September. The business delegation is a flagship activity of the Australian Innovation Showcase in India 2014. This is an initiative of the Australian Trade Commission and the Australian Government to promote Australia’s world class research capability and innovative technologies, and to help develop new trade and investment opportunities.
(17th September, 2014); Dr Harsh Vardhan, Union Health Minister, said today that the government is placing the highest importance on popularizing holistic treatment by establishing preventive and promotive care facilities for and traditional medicine throughout the country.
(17th September, 2014); The U.S. Food and Drug Administration today approved Movantik (naloxegol), an oral treatment for opioid-induced constipation in adults with chronic non-cancer pain.